Ranbaxy Laboratories Ltd. and Merck & Co., Inc have signed a strategic Product Development Agreement for a drug discovery and clinical development collaboration for new products, in the anti-infective field.
Ranbaxy and Merck will work together to develop clinically validated anti-bacterial and anti-fungal drug candidates. Ranbaxy will carry-out drug discovery and clinical development through phase IIa clinical trials, with Merck conducting development and commercialization of drug candidates thereafter.
The details can be read here.
No comments:
Post a Comment